Singapore
HEMO BIOENGINEERING LTD is a fast-growing platform company based in Singapore that focuses on developing innovative neuro- and peripheral interventional medical devices for the improvement of patients' health and quality of life. The company offers a portfolio of neuro-interventional products covering ischemic stroke, hemorrhagic stroke, and neuro access, with a particular emphasis on the groundbreaking Afentta® aspiration catheter.
The company is actively seeking potential distributors and partners for their medical device products in various markets and can be contacted via [email protected]. Founded in 2017, HEMO BIOENGINEERING LTD has made significant strides in the industry and has received a Series B investment on 19 October 2020 from Legend Capital, ISVI, and Hillhouse Ventures.
With an extensive R&D network that includes centers in Singapore, China, and the U.S., as well as a team of industry veterans from established MNCs and Fortune 500 companies, HEMO BIOENGINEERING LTD is well-positioned to continue its growth trajectory and make a notable impact in the Health Care, Manufacturing, and Medical Devices industries.
